-+ 0.00%
-+ 0.00%
-+ 0.00%

Sanofi says FDA approves Sarclisa Escena subcutaneous formulation via portable injector

PUBT·07/10/2026 12:35:32
Listen to the news
Sanofi says FDA approves Sarclisa Escena subcutaneous formulation via portable injector
  • FDA cleared Sarclisa Escena, a subcutaneous version of Sarclisa, across all existing US multiple myeloma indications for the IV formulation.
  • Launch features Enable Injections’ CirCLIQ wearable injector, billed as the first US cancer therapy delivered via a portable injector.
  • Phase 3 IRAKLIA showed non-inferior efficacy versus IV, with fewer systemic administration reactions (1.5% vs 25%).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607100834OMX_____CNEWS_FR_GNW1001212222_fr) on July 10, 2026, and is solely responsible for the information contained therein.